Accord Healthcare Recalls Cinacalcet Tablets Due to Nitrosamine Contamination
Accord Healthcare is recalling Cinacalcet 30mg tablets nationwide due to a nitrosamine impurity (N-nitroso-cinacalcet) exceeding acceptable daily intake limits. Patients should consult their healthcare provider to confirm if their medication is affected.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall for a pharmaceutical contaminant (nitrosamine) exceeding acceptable daily intake limits. No reported illnesses or injuries are stated in the source, making the hazard theoretical rather than realized, which caps the score at 3 per the rubric.
Plain-English summary
Accord Healthcare, Inc. is recalling Cinacalcet 30mg tablets in a nationwide recall in the United States and Puerto Rico. The affected product is available in two package sizes: 30 tablets per bottle (NDC: 16729-440-10) and 90 tablets per bottle (NDC: 16729-440-15).
The recall is due to Current Good Manufacturing Practice (CGMP) deviations involving the detection of a nitrosamine impurity, N-nitroso-cinacalcet, present in the product at levels exceeding the acceptable daily intake (ADI) limit.
Patients taking Cinacalcet from the affected lot numbers should contact their healthcare provider or pharmacist to determine if their medication is included in the recall. Patients should not stop taking their medication without consulting their healthcare provider.
For more information about the affected lot numbers and expiry dates, patients and healthcare providers should contact Accord Healthcare, Inc. or check the FDA's official recall notice.
The recalled product
- Product
- CINACALCET (CINACALCET)
- Brand
- CINACALCET
- Manufacturer
- ACCORD HEALTHCARE, INC.
- Hazard
- nitrosamine
- manufacturing-defect
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · CINACALCET
- HighCinacalcet prescription drug recalled for nitrosamine impurity and manufacturing deviations
FDA (Drugs) · 2026-04-22
- HighFDA Recalls Cinacalcet Tablets for N-Nitroso Impurity Exceeding Limits
FDA (Drugs) · 2026-04-22
- HighCinacalcet tablets recalled due to N-nitroso impurity above acceptable limits
FDA (Drugs) · 2026-04-22
- HighDrug Recall: Cinacalcet tablets contain excess nitrosamine impurity
FDA (Drugs) · 2025-12-17
- HighCinacalcet tablets recalled for nitrosamine impurity above acceptable limits
FDA (Drugs) · 2025-12-17
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27